Enlaye | $1,700,000 | (Oct 2, 2024)
Numa(US) | $32,000,000 | (Oct 2, 2024)
Hyivy Health | $2,000,000 | (Oct 2, 2024)
Certified by Founder
Lodge
LoQus23 Therapeutics Ltd
start up
United Kingdom
- Cambridge, Cambridgeshire
- 02/10/2024
- Series A
- $46,550,175
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
- Industry Biotechnology Research
- Website https://loqus23.com/
- LinkedIn https://www.linkedin.com/company/loqus23-therapeutics-ltd/
Indiegraf | $2,200,000 | (Oct 2, 2024)
DocJuris | $8,000,000 | (Oct 2, 2024)
Nusano | $115,000,000 | (Oct 2, 2024)
Thread AI | $6,000,000 | (Oct 2, 2024)
SETTLE PAYMENTS | $2,000,000 | (Oct 1, 2024)
Atlas Metrics | $13,557,579 | (Oct 1, 2024)